TY  - JOUR
A1  - Ebenbeck, Nikola
A1  - Rieser, Jakob
A1  - Jungjohann, Jana
A1  - Gebhardt, Markus
T1  - How the existence of special schools affects the placement of students with special needs in inclusive primary schools
JF  - Journal of Research in Special Educational Needs
N2  - Although inclusion is the declared goal, the transition from a system based on special schools to an inclusive school system has only been progressing very slowly in individual countries. In an evolving school system, the existing special schools keep struggling to justify their existence. This study investigates the regional distribution effects based on official school data and shows the influence of a pull effect on special schools as a distance effect of special schools affecting the placement of students. For this purpose, official school statistics including all students at special and regular schools in the years 2010, 2015 and 2020 (N = 11 280 040) are evaluated in a spatiotemporal comparison using Educational Data Mining. In a hierarchical regression model on school placement in inclusive schools, the distance between primary and special schools has the highest influence (β = 0.48) on the inclusion rate (i.e., the proportion of students with special needs who are educated in regular schools in relation to all students with disabilities), along with the size (β = −0.14) and the density of special schools in a district (β = −0.12). The effects differ according to the population density of the region and are stronger in large cities. When the proportion of students with and without SEN in regular schools is considered (support rate), the density of special schools has the greatest impact on school placement (ß = 43.44). Self‐preservation of schools, traditional funding systems and regional differences between urban and rural areas are discussed as possible reasons.
KW  - Inclusion Rate
KW  - placement
KW  - pull effect
KW  - school statistics
KW  - special schools
KW  - systemic effects
Y1  - 2022
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-287308
VL  - 22
IS  - 3
SP  - 274
EP  - 287
ER  - 
TY  - JOUR
A1  - Haist, Maximilian
A1  - Stege, Henner
A1  - Lang, Berenice Mareen
A1  - Tsochataridou, Aikaterini
A1  - Salzmann, Martin
A1  - Mohr, Peter
A1  - Schadendorf, Dirk
A1  - Ugurel, Selma
A1  - Placke, Jan-Malte
A1  - Weichenthal, Michael
A1  - Gutzmer, Ralf
A1  - Leiter, Ulrike
A1  - Kaatz, Martin
A1  - Haferkamp, Sebastian
A1  - Berking, Carola
A1  - Heppt, Markus
A1  - Tschechne, Barbara
A1  - Schummer, Patrick
A1  - Gebhardt, Christoffer
A1  - Grabbe, Stephan
A1  - Loquai, Carmen
T1  - Response to first-line treatment with immune-checkpoint inhibitors in patients with advanced cutaneous squamous cell carcinoma: a multicenter, retrospective analysis from the German ADOReg registry
JF  - Cancers
N2  - Cutaneous squamous cell carcinoma (cSCC) is a common malignancy of the skin and has an overall favorable outcome, except for patients with an advanced stage of the disease. The efficacy of checkpoint inhibitors (CPI) for advanced cSCC has been demonstrated in recent clinical studies, but data from real-world cohorts and trial-ineligible cSCC patients are limited. We retrospectively investigated patients with advanced cSCC who have been treated with CPI in a first-line setting at eight German skin cancer centers registered within the multicenter registry ADOReg. Clinical outcome parameters including response, progression-free (PFS) and overall survival (OS), time-to-next-treatment (TTNT), and toxicity were analyzed and have been stratified by the individual immune status. Among 39 evaluable patients, the tumor response rate (rwTRR) was 48.6%, the median PFS was 29.0 months, and the median OS was not reached. In addition, 9 patients showed an impaired immune status due to immunosuppressive medication or hematological diseases. Our data demonstrated that CPI also evoked tumor responses among immunocompromised patients (rwTRR: 48.1 vs. 50.0%), although these responses less often resulted in durable remissions. In line with this, the median PFS (11 vs. 40 months, p = 0.059), TTNT (12 months vs. NR, p = 0.016), and OS (29 months vs. NR, p < 0.001) were significantly shorter for this patient cohort. CPI therapy was well tolerated in both subcohorts with 15% discontinuing therapy due to toxicity. Our real-world data show that first-line CPI therapy produced strong and durable responses among patients with advanced cSCC. Immunocompromised patients were less likely to achieve long-term benefit from anti-PD1 treatment, despite similar tumor response rates.
KW  - advanced cutaneous squamous cell carcinoma
KW  - checkpoint inhibitor therapy
KW  - cemiplimab
KW  - immunosuppression
KW  - response durability
KW  - real-world data
Y1  - 2022
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-297506
SN  - 2072-6694
VL  - 14
IS  - 22
ER  -